ReviewFrontiers in immunology2026
Single-cell dissection of hepatocellular carcinoma immunity: from heterogeneous subtypes to precision therapeutics.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) represents one of the most prevalent malignancies worldwide and poses a critical public health challenge due to difficulties in early diagnosis, therapy resistance, and high mortality rates. The complex tumor microenvironment (TME) of HCC plays a pivotal role in tumor progression, immune evasion, metastasis, and treatment resistance. Single-cell sequencing (scRNA-seq) has emerged as a revolutionary tool for resolving the intricacies and cellular heterogeneity of the TME, with its applications in advancing therapeutic research attracting considerable attention. As the primary battleground for antitumor immune responses, the HCC tumor TME warrants comprehensive analysis of immune cell subsets at distinct developmental and functional states to elucidate the complexity of tumor immunology. This review synthesizes extensive research on TME immune cellular subpopulations, in order to summarize mainstream classifications of immune subsets at single-cell resolution and analyze their functional significance and therapeutic value through biomarker gene profiling.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.